Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies

NCT01943292 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Hematologic Cancers

Interventions

DRUG: Defactinib

Sponsor

Verastem, Inc.